BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

851 related articles for article (PubMed ID: 21544079)

  • 1. Case definition and phenotype standardization in drug-induced liver injury.
    Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
    Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury.
    Ozer JS; Chetty R; Kenna G; Palandra J; Zhang Y; Lanevschi A; Koppiker N; Souberbielle BE; Ramaiah SK
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):237-46. PubMed ID: 19903504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiosyncratic drug-induced liver injury: an update on the 2007 overview.
    Hussaini SH; Farrington EA
    Expert Opin Drug Saf; 2014 Jan; 13(1):67-81. PubMed ID: 24073714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting and preventing acute drug-induced liver injury: what's new in 2010?
    Liss G; Rattan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method.
    Teschke R
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1169-1187. PubMed ID: 30354694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causality assessment in drug-induced liver injury.
    Hayashi PH
    Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
    Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
    Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced liver injury: what was new in 2008?
    Liss G; Lewis JH
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):843-60. PubMed ID: 19505188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver enzyme abnormalities during concurrent use of herbal and conventional medicines in Korea: a retrospective study.
    Kim NH; Jung HY; Cho SY; Park SU; Park JM; Ko CN
    Phytomedicine; 2011 Nov; 18(14):1208-13. PubMed ID: 21802919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):317-22. PubMed ID: 2272712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.
    Weber S; Benesic A; Rotter I; Gerbes AL
    Liver Int; 2019 Oct; 39(10):1906-1917. PubMed ID: 31319011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.
    Fontana RJ; Watkins PB; Bonkovsky HL; Chalasani N; Davern T; Serrano J; Rochon J;
    Drug Saf; 2009; 32(1):55-68. PubMed ID: 19132805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.
    Pirmohamed M; Aithal GP; Behr E; Daly A; Roden D
    Clin Pharmacol Ther; 2011 Jun; 89(6):784-5. PubMed ID: 21593754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced liver injury.
    Leise MD; Poterucha JJ; Talwalkar JA
    Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and Need for Extended Immunosuppression: Novel Features of Drug-Induced Autoimmune Hepatitis.
    Weber S; Gerbes AL
    Digestion; 2023; 104(3):243-248. PubMed ID: 36603570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools.
    Au JS; Navarro VJ; Rossi S
    Aliment Pharmacol Ther; 2011 Jul; 34(1):11-20. PubMed ID: 21539586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic liver injury induced by drugs and toxins.
    Ortega-Alonso A; Andrade RJ
    J Dig Dis; 2018 Sep; 19(9):514-521. PubMed ID: 29808546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.